MiNK Therapeutics (FRA:6Q40) Float Percentage Of Total Shares Outstanding: 48.87% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Q40 MiNK Therapeutics Inc FRA:6Q40
21 GF Score
Price €9.00
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics Float Percentage Of Total Shares Outstanding?

MiNK Therapeutics FRA:6Q40 +4.65% 21 Float Percentage Of Total Shares Outstanding is 48.87% as of Jul. 16, 2026. GuruFocus rates FRA:6Q40 with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MiNK Therapeutics's float shares is 2.43 Mil. MiNK Therapeutics's total shares outstanding is 4.98 Mil. MiNK Therapeutics's float percentage of total shares outstanding is 48.87%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MiNK Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MiNK Therapeutics's Institutional Ownership is 2.43%.

FRA:6Q40
21GF Score
MiNK Therapeutics Inc FRA:6Q40
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MiNK Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2.43/4.98
=48.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 48.87% mean?
MiNK Therapeutics (FRA:6Q40) has a Float Percentage Of Total Shares Outstanding of 48.87% as of Jul. 16, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' Float Percentage Of Total Shares Outstanding too high?
MiNK Therapeutics' current Float Percentage Of Total Shares Outstanding is 48.87%. Overall, MiNK Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Float Percentage Of Total Shares Outstanding compare to BOLD and FLNA?
MiNK Therapeutics' Float Percentage Of Total Shares Outstanding of 48.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current Float Percentage Of Total Shares Outstanding is 48.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (FRA:6Q40) has a current Float Percentage Of Total Shares Outstanding of 48.87%. The current Float Percentage Of Total Shares Outstanding is 48.87%. MiNK Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For MiNK Therapeutics (FRA:6Q40), the current Float Percentage Of Total Shares Outstanding is 48.87% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges INKT:USA
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
21GF Score

Get the complete analysis for FRA:6Q40

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.00
Price